{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:09:37Z","timestamp":1792782577385,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidad de la Rioja","id":[{"id":"https:\/\/ror.org\/0553yr311","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell\u2013associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.<\/jats:p>","DOI":"10.1007\/s00277-026-07105-x","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:37:11Z","timestamp":1782481031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Effector Cell\u2013associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8972-7006","authenticated-orcid":false,"given":"Sof\u00eda","family":"Rinc\u00f3n-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3201-3909","authenticated-orcid":false,"given":"Ricardo","family":"Garc\u00eda-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5217-6319","authenticated-orcid":false,"given":"Johelys","family":"Atencio-Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0871-8198","authenticated-orcid":false,"given":"Olalla","family":"Pereda-Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1660-5228","authenticated-orcid":false,"given":"Javier","family":"Larreina-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Campeny-Najara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Herrera","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Hern\u00e1ndez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-8813","authenticated-orcid":false,"given":"Jes\u00fas","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-0999","authenticated-orcid":false,"given":"Ada","family":"Esteban-Figuerola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"26","key":"7105_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"7105_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"4","key":"7105_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"7105_CR4","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"NV Frey","year":"2019","unstructured":"Frey NV, Porter DL (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl 25(4):e123\u2013e127. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.756","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"7105_CR5","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S et al (2023) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transpl Cell Ther 29(7):438.e1-438.e16.https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"7105_CR6","doi-asserted-by":"publisher","first-page":"239e1","DOI":"10.1016\/j.jtct.2023.01.012","volume":"29","author":"IEC-HS ASTCT Working Group","year":"2023","unstructured":"IEC-HS ASTCT Working Group (2023) Immune effector cell\u2013associated hemophagocytic syndrome (IEC-HS): diagnostic criteria and management recommendations. Transpl Cell Ther 29(4):239e1\u2013239e8. https:\/\/doi.org\/10.1016\/j.jtct.2023.01.012","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"7105_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41571-021-00470-6","volume":"18","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S et al (2021) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy. Nat Rev Clin Oncol 18(6):371\u2013390. https:\/\/doi.org\/10.1038\/s41571-021-00470-6","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"7105_CR8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA et al (2017) Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698","journal-title":"Cancer Discov"},{"issue":"6","key":"7105_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24(6):739\u2013748. https:\/\/doi.org\/10.1038\/s41591-018-0036-4","journal-title":"Nat Med"},{"issue":"23","key":"7105_CR10","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465\u20132477. https:\/\/doi.org\/10.1182\/blood.2018894618","journal-title":"Blood"},{"issue":"9","key":"7105_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","volume":"27","author":"R Ram","year":"2021","unstructured":"Ram R, Hagin D, Kikozashvilli N et al (2021) Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy. Transpl Cell Ther 27(9):788\u2013794. https:\/\/doi.org\/10.1016\/j.jtct.2021.06.024","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"7105_CR12","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41591-021-01387-6","volume":"27","author":"L Au","year":"2021","unstructured":"Au L, Fendler A, Shepherd STC et al (2021) Cytokine release syndrome in a patient with metastatic cancer following COVID-19 vaccination. Nat Med 27(8):1362\u20131366. https:\/\/doi.org\/10.1038\/s41591-021-01387-6","journal-title":"Nat Med"},{"issue":"16","key":"7105_CR13","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/bloodadvances.2021005251","volume":"5","author":"JM Rocco","year":"2021","unstructured":"Rocco JM, Mallajosyula V, Tomkins-Tinch C et al (2021) Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. Blood Adv 5(16):3284\u20133288. https:\/\/doi.org\/10.1182\/bloodadvances.2021005251","journal-title":"Blood Adv"},{"key":"7105_CR14","unstructured":"Masi\u00e1 M, Fern\u00e1ndez-Gonz\u00e1lez M, Padilla S et al Inflammatory syndromes following COVID-19 vaccination: a systematic review. Clin Microbiol Infect"},{"issue":"13","key":"7105_CR15","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020001817","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati P, Nastoupil LJ, Westin JR et al (2020) Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123\u20133127. https:\/\/doi.org\/10.1182\/bloodadvances.2020001817","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07105-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:04:54Z","timestamp":1791673494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07105-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7105"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07105-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent could not be obtained from the patient due to death. Written informed consent for publication was obtained from the patient\u2019s next-of-kin. All patient data included in this report were fully anonymized and no identifiable personal information is disclosed. According to institutional policies, specific written consent for publication was not required.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"413"}}